Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.

Bernard Royer 1, 2 Delphine Delroeux 3 Emmanuel Guardiola 4 Marielle Combe 5 Guillaume Hoizey 6 Damien Montange 1 Jean-Pierre Kantelip 1 Bruno Chauffert 7 Bruno Heyd 3 Xavier Pivot 2, 4
1 Laboratoire de Pharmacologie Clinique et Toxicologie [Besancon]
2 HOTE GREFFON - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
3 Service de chirurgie viscérale et digestive - Unité de transplantation hépatique
4 Service d'oncologie Médicale
5 Département d'Anesthésie
6 URCA - Université de Reims Champagne-Ardenne
7 Mort cellulaire et cancer
Abstract : Ovarian cancer is the leading cause of gynecological cancer-related death in Western countries. The present treatment standards for ovarian cancer are based on the association of debulking surgery with platinum-based chemotherapy. Another strategy that could be further investigated is intraperitoneal chemotherapy (IP). We previously described that the 2-h administration of intraoperative IP cisplatin did not reach satisfactory concentrations. In the present study, we present the results of a pharmacokinetic analysis performed after two consecutive 1-h IP 30 mg/l cisplatin administrations. Twenty-seven patients with advanced epithelial cancer classified FIGO stage IIIC were included in the study. Blood and IP samples were taken over a 24-h period, during and after IP treatment. Both total and ultrafiltered (Uf) platinum (Pt) concentration levels were analyzed. Biological and clinical toxicities were also recorded. With this strategy, IP Pt concentrations stayed above the target concentration (10 mg/l) for a satisfactory length of time. The serum Pt concentrations were higher than those observed with the "one-bath" protocol and they induced the occurrence of recoverable renal toxicities (3 grade 1, 7 grade 2 and 4 grade 3). The best predictive parameter for renal failure was the total Pt 24-h Area Under the Curve (AUC) with a threshold value of 25 mg h/l RR = 0.31 (95% CI 0.13 - 0.49, P < 0.01). Administration of an increased amount of cisplatin is feasible and a satisfactory level of IP Pt concentrations is obtained. However, this improvement is associated with an increase in serum Pt levels and resulting renal toxicities. An attractive solution would be to decrease Pt transfer from peritoneum to bloodstream. A phase 1 study using intraoperative IP epinephrine in order to decrease this transfer is presently being carried out.
Type de document :
Article dans une revue
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2008, 61 (3), pp.415-21. 〈10.1007/s00280-007-0484-x〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00483417
Contributeur : Philippe Saas <>
Soumis le : vendredi 14 mai 2010 - 11:42:05
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Lien texte intégral

openaccess

Identifiants

Collections

UNIV-FCOMTE | UMR645 | URCA

Citation

Bernard Royer, Delphine Delroeux, Emmanuel Guardiola, Marielle Combe, Guillaume Hoizey, et al.. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.. Cancer Chemotherapy and Pharmacology, Springer Verlag, 2008, 61 (3), pp.415-21. 〈10.1007/s00280-007-0484-x〉. 〈inserm-00483417〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

286

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD